LRRC32 and melanoma: In melanoma cells, GARP has been shown to be expressed on the surface of tumor cells, modulating and inhibiting antigen-specific T effector cell responses, and inducing peripheral regulatory T cells [21], thus, contributing to the immune-inhibitory tumor microenvironment.